AZD2962

Phase 1Small molecule

AstraZeneca

AZD2962 is one of 5 small molecule programs targeting Blood Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Blood CancerRecruiting

Blood CancerPhase 1

Recruiting

Competition

Competitive Landscape

6 competitors in Blood Cancer

#DrugCompanyPhaseTrials

Jaypirca

Eli Lilly

Phase 2

1 2

COVID-19 Vaccine

Moderna

Phase 2

1 3

Koselugo

AstraZeneca

Phase 1

1 4

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

1 5

AZD2962

AstraZeneca

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Blood Cancer

NCT07064122

Clinical

Trials by Indication[1]

Blood Cancer1 trial

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07064122·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AZD2962. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD2962 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD2962. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AstraZeneca

AZD2962

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Blood Cancer1 trial

References

Drug Info

Quick Facts

Related News